Collegium Pharmaceutical Earnings Call Transcripts
Fiscal Year 2026
-
2026 guidance projects steady revenue and EBITDA growth, led by strong ADHD franchise expansion and the AZSTARYS acquisition, which is expected to be immediately accretive. Pain portfolio remains stable despite generic pressures, and capital strategy balances growth investments with financial discipline.
-
The acquisition of AZSTARYS adds a differentiated ADHD medicine, extends exclusivity to 2037, and is expected to be immediately accretive to EBITDA. Operational synergies and a larger sales force are anticipated to drive growth and cost savings, with the deal closing expected in Q2 2026.
-
Record-breaking 2025 performance was driven by JORNAY PM's rapid growth and a stable pain portfolio. 2026 guidance projects continued strong demand for JORNAY PM and stable pain franchise revenues, supported by disciplined capital allocation and a robust balance sheet.
Fiscal Year 2025
-
Record 2025 results with 24% revenue and 15% adjusted EBITDA growth, driven by strong performance in both ADHD and pain portfolios. 2026 guidance anticipates continued double-digit growth for Jornay PM and stable pain revenues, supported by strategic capital deployment and a new $980M credit facility.
-
Jornay PM continues to drive growth with strong prescription gains and expanded sales coverage, supported by improved gross-to-net and favorable market dynamics. The pain franchise maintains exclusivity with limited generic threats, while capital deployment focuses on business development, shareholder returns, and debt reduction.
-
Significant revenue and EBITDA growth is driven by differentiated pain and ADHD products, with Jornay PM as a key growth driver. Strategic investments in sales and marketing, durable pain portfolio revenues, and disciplined capital deployment support a strong outlook.
-
Record Q3 revenue and EBITDA were driven by strong growth in both ADHD and pain portfolios, prompting raised 2025 guidance. Jornay PM prescriptions and market share surged, while capital deployment remained disciplined with share repurchases and debt repayment.
-
Strong net sales growth is driven by differentiated pain and ADHD products, with JORNAY PM gaining market share through expanded sales efforts and targeted DTC campaigns. The pain portfolio remains resilient, and disciplined capital allocation supports ongoing acquisitions, share repurchases, and debt reduction.
-
Management highlighted strong growth in ADHD and pain portfolios, with raised revenue guidance and robust commercial execution. Strategic investments in sales force and awareness are expected to drive further gains, while the pain franchise's durability and cash flow support ongoing business development and shareholder returns.
-
Record Q2 revenue and adjusted EBITDA growth were driven by JORNAY and the pain portfolio, prompting raised 2025 guidance. JORNAY prescriptions surged 23% year-over-year, with strong adult segment growth and expanded sales force support. Cash flow and capital deployment remain robust.
-
A diversified biopharma company reported strong 2024 sales and projects 18% revenue growth for 2025, driven by differentiated chronic pain and ADHD products. Strategic investments in sales and marketing, robust exclusivity, and disciplined capital allocation support long-term growth and revenue durability.
-
Q1 2025 saw 23% revenue growth, led by Jornay's 24% prescription increase and strong pain portfolio performance. Expanded sales force and targeted investments support guidance for 18% revenue growth in 2025, with continued debt reduction and share repurchases.
-
A diversified biopharma company projects 18% revenue growth in 2025, driven by strong performance of Jornay PM and a resilient pain portfolio. Strategic focus remains on commercial-stage BD, disciplined capital allocation, and leveraging U.S.-based operations for stability.
Fiscal Year 2024
-
Revenue grew 11% and adjusted EBITDA 9% in 2024, driven by pain portfolio strength and Jornay PM acquisition. 2025 guidance projects continued double-digit growth, with major investments in Jornay PM and robust cash flow supporting share repurchases and debt reduction.
-
Leadership aims to diversify beyond pain, leveraging recent acquisitions and a strong financial base. Jornay PM integration is a key focus, with plans to expand the sales force and target both pediatric and adult ADHD markets. Pain franchise growth continues, with disciplined execution and strategic capital deployment supporting future expansion.
-
Record Q3 revenues and EBITDA were driven by strong growth in Belbuca, Xtampza, and the newly acquired JORNAY PM, which showed robust script growth and broad coverage. Leadership transition to a new CEO aims to sustain organic and inorganic growth, while capital allocation focuses on business development, debt reduction, and share repurchases.
-
Record Q3 2024 results featured 17% revenue growth, strong pain portfolio performance, and rapid JORNAY PM integration. 2024 guidance reaffirmed, with JORNAY PM expected to exceed $100 million in net revenue and new CEO appointed to drive future growth.
-
The company completed the Ironshore acquisition, expanding into ADHD with Jornay PM, a differentiated, high-margin product expected to exceed $150 million in peak sales. Financial guidance was raised, and the base pain business continues to perform as expected, with further growth opportunities identified.
-
Q2 2024 saw 7% revenue and 12% adjusted EBITDA growth, record BELBUCA sales, and strong cash flow. The proposed Ironshore acquisition adds JORNAY PM, expected to exceed $100M in 2024 revenue, diversifying the portfolio and supporting future growth.
-
The acquisition of Ironshore and its ADHD drug Jornay PM diversifies the portfolio, expands into neurology, and is expected to be immediately accretive to EBITDA. The deal is funded by cash and a new loan, with integration plans to maintain both sales teams and leverage commercial strengths.
-
Q1 results met expectations with strong EBITDA growth and stable guidance. BELBUCA leads portfolio growth, while Nucynta and Xtampza show resilience amid IP and contract changes. CEO transition was planned, strategy remains unchanged, and capital return continues.